Peter Virsik - 07 Oct 2024 Form 4 Insider Report for ESSA Pharma Inc. (EPIX)

Reporting relationship: Chief Operating Officer
Issuer ticker: EPIX
Reported as of: 07 Oct 2024
Net transaction value: -$4,185
SEC form: 4
Accepted by SEC: 07 Oct 2024, 15:00:52 UTC
Prior SEC filing: 09 Sep 2024
Source filing: View source filing
Reporting owner signature: /s/ Peter Virsik

Key filing fact

Peter Virsik filed Form 4 for ESSA Pharma Inc. (EPIX) on 07 Oct 2024.

Key facts

This page summarizes Peter Virsik's Form 4 filing for ESSA Pharma Inc. (EPIX).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 07 Oct 2024, 15:00.

Change

Previous filing in this sequence was filed on 09 Sep 2024.
Current net transaction value: -$4,185.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

EPIX transaction

Common Shares

Sale

Transaction value: $4,185
Shares: -694
Change %: -8.2%
Price: $6.03
Shares after: 7,776
Date: 07 Oct 2024
Ownership: Direct
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 2 footnotes

Footnote F1

The amount reflects the sale of shares pursuant to Mr. Virsik's 10b5-1 trading plan. The Rule 10b5-1 trading plan was entered into on August 31, 2023.

Footnote F2

The price reported in Column 4 is a weighted average price. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.